pms-Citalopram

Citalopram hydrobromide.

Each film-coated tablet contains 20 mg citalopram (as citalopram hydrobromide).
Proper name: Citalopram hydrobromide.
Chemical name: 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran-carbonitrile monohydrobromide; or (1RS)-1-[3-(dimethylamino)propyl-1-(4-fluorophenyl)-1,3-dihydro-isobenzofurane-5-carbonitrile hydrobromide; or 1-[3-(Dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile monohydrobromide.
Molecular formula: C₂₀H₂₂BrFN₂O.
Molecular mass: 405.31 g/mol.
Physicochemical properties: White or almost white crystalline powder. Odourless or almost odourless. Its melting point is between 184°C and 188°C, its pH between 5.5 to 6.5 (0.5% w/v in water), and its pKa is 9.5 (microtitration). It is sparingly soluble in water, soluble in ethanol, freely soluble in chloroform and very slightly soluble in diethylether.
Excipients/Inactive Ingredients: Colloidal silicon dioxide, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate and titanium dioxide.

Pharmacology: Pharmacodynamics: Citalopram has no or very low affinity for a series of receptors including serotonin 5-HT_1A, 5-HT₂, dopamine D₁ and D₂, α₁-, α₂-, β-adrenergic, histamine H₁, muscarinic cholinergic, benzodiazepine, gamma aminobutyric acid (GABA) and opioid receptors.
Mechanism of Action: Citalopram is a highly selective and potent serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor with minimal effects on the neuronal reuptake of norepinephrine (NE) and dopamine (DA). The ability of citalopram to potentiate serotonergic activity in the central nervous system via inhibition of the neuronal reuptake of serotonin is thought to be responsible for its antidepressant action. Tolerance to the inhibition of serotonin reuptake is not induced by long-term (14 days) treatment of rats with citalopram.
Clinical Trials: Comparative Bioavailability Studies: A blind, randomized, 2-way crossover, bioequivalence study between Pharmascience's pms-CITALOPRAM 40 mg tablets was performed versus Lundbeck's Celexa, administered as 1x 40 mg tablets in 22 healthy male volunteers under fasting conditions. Pharmacokinetic and bioavailability data are presented in the following table: See Table 1.

Click on icon to see table/diagram/image

Study Results: The efficacy of citalopram hydrobromide in the treatment of depression was established in five placebo-controlled studies in patients who met the DSM-III or DSM-III-R criteria for major depression. Response to treatment was evaluated by the Hamilton Depression Rating Scale (HAMD) and/or the Montgomery Asberg Depression Rating Scale (MADRS), as well as the Clinical Global Impression (CGI) Severity Scale. On the HAMD and MADRS, total scores, selected single items, and percentage of responders (defined as patients whose HAMD/MADRS total score decreased by at least 50% versus baseline) were assessed.
In a 6-week fixed-dose, dose-response study, patients received citalopram hydrobromide, at doses of 10, 20, 40, or 60 mg/day or placebo (n=129 to 131 per group). The 40 and 60 mg/day doses were titrated, with patients reaching these designated doses within 4 and 8 days, respectively. The study showed that the 40 and 60 mg/day doses were significantly more effective than placebo, although the 60 mg/day dose was not more effective than the 40 mg/day dose. The lower doses did not show statistically significant superiority over placebo, except on the MADRS; on this scale the percent of 'responders' was significantly higher in all the citalopram hydrobromide-treated groups than in the placebo-treated group.
The second study was a 4-week flexible-dose study in which 85% of the depressed patients met the criteria for melancholia. At entry, 89 and 91 patients were randomized to the citalopram hydrobromide and placebo groups, respectively. This was the only study in which more male than female patients participated (64% vs. 36%). The initial dose of citalopram hydrobromide, 20 mg/day, could be titrated to the maximal tolerated dose or a maximum dose of 80 mg/day. Patients treated with citalopram hydrobromide showed significantly greater improvement than patients treated with placebo. At week 4, the average daily dose was 63 mg, with 52% of patients receiving the 80 mg/day dose.
In a 6-week fixed-dose study, patients received citalopram hydrobromide, 20 or 40 mg/day, or placebo (n=64 to 70 per group). Patients treated with citalopram hydrobromide, 40 mg/day, showed significantly greater improvement than placebo-treated patients. The difference between the lower dose of citalopram hydrobromide and placebo was not significant.
In another 6-week fixed-dose study, patients received citalopram hydrobromide, 20 or 40 mg/day or placebo (n=88 to 97 per group). Although citalopram hydrobromide-treated patients improved to a somewhat greater degree than the placebo-treated patients, the differences between drug and control groups did not reach statistical significance due to a high placebo response, i.e., substantial improvement in the placebo group.
A 6-week, flexible-dose study was conducted in elderly, depressed patients (the mean age of male and female patients was 75 and 77 years, respectively) to determine the antidepressant effect and safety of citalopram hydrobromide in this subpopulation. The number of patients who received citalopram hydrobromide and placebo was 98 and 51, respectively. The study allowed patients to enter with lower baseline HAMD scores than are usually acceptable (≥18 in clinical trials). However, only a small percentage of patients had HAMD scores of less than 18 at entry. The dose of citalopram hydrobromide was titrated from a starting dose of 10 mg/day to a maximum dose of 30 mg/day. Patients treated with citalopram hydrobromide showed significantly greater improvement than patients treated with placebo. The final dose of citalopram hydrobromide was 10, 20 and 30 mg/day in 5%, 51% and 44% of patients, respectively.
The effectiveness of citalopram hydrobromide in preventing relapse was assessed in two long-term studies. Depressed patients who responded to citalopram hydrobromide during an initial 6 or 8 weeks of acute treatment (fixed doses of 20 or 40 mg/day in one study and flexible doses of 20-60 mg/day in the second study) were randomized to continue on citalopram hydrobromide or receive placebo. The number of patients who received citalopram hydrobromide and placebo was 257 and 116, respectively. In both studies, patients who continued on citalopram hydrobromide experienced significantly lower relapse rates over the subsequent 6 months compared to those receiving placebo. In the fixed-dose study, the relapse rates were similar at the 20 and 40 mg/day doses, namely 10% and 12%, respectively. Of the placebo-treated patients, 31% experienced relapse. In the flexible-dose study, the relapse rates were 14% and 24% in the citalopram hydrobromide- and placebo-treated patients, respectively. While the majority of patients (76%) were maintained on 20 or 40 mg/day of citalopram hydrobromide during most of the study, some patients received 60 mg/day, while a few patients were maintained on less than 20 mg/day.
Detailed Pharmacology: Pharmacodynamics: Citalopram is a racemic mixture with the S (+) enantiomer mediating the pharmacological effects. The R (-) enantiomer contributes little to the activity of citalopram.
In Vitro Experiments: (a) Neuronal reuptake of serotonin, norepinephrine and dopamine: The primary pharmacological effect of citalopram is inhibition of the 5-HT reuptake mechanism. Citalopram was shown to inhibit 5-HT uptake in rabbit blood platelets, with an IC₅₀ of 14 nM. Similarly, the drug inhibits 5-HT uptake in rat brain synaptosomal preparations. (See Table 2.)

Click on icon to see table/diagram/image

The data indicate that citalopram is a potent and specific 5-HT uptake inhibitor with no activity on the neuronal reuptake of norepinephrine (NE) or dopamine (DA). The metabolites of citalopram are also specific inhibitors of 5-HT reuptake, albeit less active than the parent drug.
The ratio between the concentrations inhibiting the in vitro uptake of NE and 5-HT determine the selectivity of a SSRI. According to this criterion citalopram is a highly selective SSRI.
(b) Effect on neurotransmitter receptors: Citalopram has no or very low affinity for a series of receptors including 5-HT_1A, 5-HT₂, dopamine D₁ and D₂ receptors, α₁-, α₂-, β-adrenoreceptors, histamine H₁, muscarinic cholinergic, benzodiazepine, and opioid receptors.
A series of functional in vitro tests in isolated organs as well as functional in vivo tests have confirmed the lack of receptor affinity.
Behavioral Effects: In a "behavioral despair paradigm", mice, trained to swim in a glass jar, eventually exhibit immobility. This behavior was dose-dependently reversed by citalopram.
The 5-HT precursors, tryptophan and 5-HTP, induce in mice and rats the 5-HT syndrome, characterized by tremor, hyperactivity, abnormal gait, lordosis, and abduction of the hind limbs. Citalopram potentiated these behavioral manifestations. The demethyl, didemethyl, and N-oxide metabolites were less potent than the parent drug.
The characteristic head twitches, induced by a combined treatment with a MAOI and 5-HTP, were potentiated by citalopram. However, head twitches induced by quipazine, a direct 5-HT mimetic, were not affected by citalopram, indicating that the drug has no anti-5-HT activity.
Although citalopram has no antinociceptive activity per se, it potentiated the antinociceptive effect of morphine. In a food reinforcement paradigm, delivered under a multiple schedule, citalopram did not affect the responding in pigeons but potentiated the 5-HTP-induced decrease in responding.
In rats, citalopram did not facilitate self-stimulation, did not substitute for d-amphetamine, d-LSD, or 8-OHDPAT in a drug discrimination paradigm and did not increase ethanol consumption in an ethanol/water preference test. In the latter experiment, citalopram actually decreased ethanol consumption. These experiments indicate that citalopram would not be abused and would not cause dependence.
Citalopram had a slight protective effect against maximal electroshock-induced convulsions, isoniazide-induced convulsions and audiogenic seizure. However, in toxicity studies convulsions have been observed at very high plasma levels of citalopram (see Toxicology as follows).
Cardiovascular Effects: Citalopram blocked heterologous HERG-mediated currents in transfected Chinese hamster ovary cells with an IC50 of 4 mcM.
In conscious dogs, single oral doses of 5 mg/kg of citalopram caused pronounced fluctuation of the blood pressure and heart rate. A 10 mg/kg dose caused tachycardia and elevated blood pressure. The ECG was unchanged.
In anaesthetized cats, single oral doses of 35 mg/kg decreased the following parameters: mean arterial blood pressure, left ventricular end diastolic pressure, contractility, cardiac performance, stroke volume, and cardiac output. Peripheral resistance was increased. ECG abnormalities included alterations in conduction, changes in rhythm and T-wave inversion in 2 of 6 cats.
Additional cardiovascular effects of citalopram and a metabolite are described under Toxicology.
Pharmacokinetics: Absorption: Following the administration of a single oral dose of citalopram (40 mg) to healthy male volunteers, peak blood levels occurred at about 4 hours (range 1 to 6 hours). The absolute bioavailability of citalopram was about 80% (range 52 to 93%) relative to an intravenous dose. Absorption was not affected by food.
Distribution: After intravenous infusion in healthy male volunteers, the apparent volume of distribution (Vd) β was about 12 L/kg (range 9-17 L/kg), indicating a pronounced tissue distribution; (Vd)β oral was about 17 L/kg (range 14-21 L/kg). The binding of citalopram and its demethylated metabolites to human plasma proteins is about 80%.
The single- and multiple-dose pharmacokinetics of citalopram are linear and dose-proportional in a dose range of 10 to 60 mg/day. Steady-state plasma levels are achieved in patients in 1-2 weeks. At a daily dose of 40 mg, the average plasma concentration is about 83 ng/mL (n=114) with a range from 30 to 200 ng/mL. Citalopram does not accumulate during long-term treatment. A clear relationship between citalopram plasma levels and therapeutic response or side effects has not been established.
Metabolism: Citalopram is metabolized in the liver to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative.
In vitro studies show that DCT, DDCT and citalopram-N-oxide also inhibit the neuronal reuptake of serotonin but are less selective and less potent than the parent compound and are of minor clinical importance. Unchanged citalopram is the predominant compound in plasma.
In vitro studies indicated that the biotransformation of citalopram to its demethyl metabolites depends on both CYP2C19 and CYP3A4, with a small contribution from CYP2D6. An initial dose of 10 mg is recommended for known poor metabolisers of CYP2C19 (see Recommended Dose and Dosage Adjustment: CYP2C19 Poor Metabolisers under Dosage & Administration).
Elimination: The elimination half-life of citalopram (t_2β) is approximately 37 hours (range: 30 - 42 hours) which allows recommendation of once-daily dosing. The systemic citalopram plasma clearance (Cl_S) is 0.33 L/min. Citalopram is eliminated primarily via the liver (85%) and the remainder via the kidneys; approximately 12% (range 6-21%) of the daily dose is excreted in urine as unchanged citalopram.
Special Populations and Conditions: Geriatrics: Elderly patients (4 males and 7 females aged 73 - 90 years), received a 20 mg/day dose of citalopram for 3-4 weeks. In the elderly, steady state plasma levels were elevated (106 ng/mL), half-life prolonged (1.5 - 3.75 days) and clearance decreased (0.08 - 0.3 L/min). Elevation of citalopram plasma levels occurred at an earlier age in females than in males. In this population, lower doses and a lower maximum dose of citalopram are recommended (see Recommended Dose and Dosage Adjustment: Geriatrics (≥ 65 years of age) under Dosage & Administration and Use in Elderly under Precautions).
Hepatic Insufficiency: The pharmacokinetics of citalopram were compared in patients with reduced hepatic function (3 female and 6 male patients aged 41 - 60 years) to those seen in 12 healthy male volunteers (aged 21 - 43 years). In patients with reduced hepatic function the half-life of citalopram was approximately doubled (83 hours vs. 37 hours), steady state citalopram concentrations increased by 61% and oral clearance decreased by 37%. Consequently, the use of citalopram in patients with reduced hepatic function should be approached with caution and lower maximal doses should be prescribed (see Recommended Dose and Dosage Adjustment: Hepatic Impairment under Dosage & Administration and Hepatic/Biliary/Pancreatic: Hepatic Impairment under Precautions).
Renal Insufficiency: In patients with mild to moderate reduction of the renal function (4 female and 3 male patients aged 30-55 years), citalopram was being eliminated more slowly than in 12 healthy male volunteers (aged 21-43 years); half-lives being 49 hours vs. 37 hours. However, mild to moderate renal impairment had no major influence on the kinetics of citalopram. At present, no information is available for chronic treatment of patients with severely reduced renal function (creatinine clearance <20 mL/min).
Pharmacokinetics in Animals: Absorption: The kinetics of citalopram in mouse, rat, and dog are characterized by rapid absorption, with T_max ranging from 0.5 to 4 hours. In contrast to man, reduced systemic bioavailability due to extensive first-pass metabolism has been demonstrated in animals.
Distribution: Pharmacokinetic analysis of single dose i.v. data suggests two-compartment distribution characteristics. High levels of drug and demethylated metabolites were found in the lungs, liver, and kidneys, and lower levels in the heart and brain. Citalopram and the demethylated metabolites were shown to pass the placental barrier and were excreted in small amounts in milk.
The plasma protein binding of citalopram has been estimated to be 70-80%. The binding protein(s) has not been identified.
Both in mice and dogs, tissue concentrations of parent drug as well as those of the demethylated metabolites increased with increasing doses, although not necessarily in a dose-related manner. Levels of the didemethylated metabolites were higher in dogs than in mice in relation to the parent drug, resulting in smaller citalopram/didemethylcitalopram ratios in the dog, particularly in the heart and kidneys.
Metabolism: There are no major qualitative differences in the metabolism of citalopram between animals and man. Citalopram is metabolized to demethylcitalopram, didemethylcitalopram, citalopram-N-oxide, and the deaminated propionic acid.
Demethylcitalopram and didemethylcitalopram levels are more prominent in mouse, rat, and dog than in man.
Elimination: Elimination of citalopram after a single dose is rapid, the half-life ranging from 1.5-2 hours in the mouse to 3.5-8 hours in the dog. In the dog, the half-life is prolonged with increasing doses due to saturation of the first-pass metabolism.
Following the administration of ¹⁴C-labelled citalopram to rats, at a dose of 20 mg/kg, approximately equal amounts of the dose were excreted in the urine and feces, with total recovery being about 80%.
Toxicokinetics: Plasma levels were determined in several long-term toxicity studies. The following table summarizes the results seen in some of these studies. (See Table 3.)

Click on icon to see table/diagram/image

The data indicate that the plasma levels of citalopram, as well as those of the demethylated metabolites, are considerably higher in animals than in man. The approximate 0.9 mg/kg dose in man corresponds to the highest recommended dose (60 mg/day). The plasma levels of the parent drug, seen in rats and dogs at the highest doses, are approximately 10 times higher in animals than in man, while the levels of the didemethyl metabolites are almost 100 fold higher. In the rat, a NOEL (no observable effect level) could not be established in this study; at the low dose minimal vacuolization of hepatocytes with fatty infiltration, and foam cell accumulation in lungs were noted. The changes were reversible. In dogs, the NOEL was 3 mg/kg.
Toxicology: Acute Toxicity: The LD₅₀ values of citalopram ranged between 900-1700 mg/kg after oral administration and 38-74 mg/kg after intravenous administration. However, some mortality was also seen in the 400-600 mg/kg dose range, indicating a very flat dose-response curve regarding mortality. Signs of toxicity were sedation and tremor, while convulsions occurred at doses close to or above the LD₅₀ values. (See Table 4.)

Click on icon to see table/diagram/image

A number of single dose toxicity studies have been carried out in dogs to investigate the potential cardiovascular toxicity of citalopram. In these studies, cardiotoxicity was not observed, but tonic-clonic convulsions were seen after oral administration of 20-40 mg/kg, as well as after slow intravenous infusion of 20-24 mg/kg. The critical plasma concentration for convulsions was about 1950 ng/mL.
Long-term Toxicity: Toxicological studies, including daily dosing for periods up to 26 weeks in mice and 52 weeks in rats and dogs, have been carried out. Plasma drug monitoring in the long-term safety studies documented that animals have been exposed to average citalopram levels of up to about 1200 ng/mL (dogs and rats) and 2900 ng/mL (mice), as well as substantial levels of demethylcitalopram [up to about 1800 ng/mL (rats), 600 ng/mL (dogs), 1150 ng/mL (mice)] and didemethylcitalopram [up to about 650 ng/mL (rats), 600 ng/mL (dogs), 300 ng/mL (mice)].
Apart from behavioral and functional characteristics of exaggerated 5-HT stimulation (e.g., hyperactivity, tremor, tail rigidity, mydriasis, reduced food consumption, and reduced body weight gain), two treatment-related findings have been demonstrated in rodents, namely fatty infiltration of the liver and lipidosis (vacuolization of lymphocytes). Both of the findings were reversible. In addition, retinal degeneration and testicular atrophy were also observed in rats.
In dogs, two treatment-related effects were found. Firstly, convulsions and death when plasma citalopram levels exceeded 1950 ng/mL (p.o. or i.v.). Secondly, fatal ventricular arrhythmias at combined high levels of the didemethyl metabolite (about 300 ng/mL) and citalopram (about 1950 ng/mL) were seen following i.v. infusion.
Hepatic Fatty Infiltration in Rodents: Fatty infiltration in the liver was first observed in a 3-month gavage study in rats given 8-32 mg/kg/day of citalopram. This administration resulted in dose-related hepatic fatty infiltration in all male rats but not in female rats at any of the doses. The fatty infiltration in male rats was also observed in a 4-week study, however, only at considerably higher doses (>160 mg/kg). In female rats only minimal fatty infiltration was seen at a 200 mg/kg/day dose.
Lipidosis (phospholipids) in Rodents: Phospholipidosis, which has been seen in rodents, is an abnormal accumulation of phospholipids in phagocytic cells and cells which catabolize biomembranes, such as pulmonary alveolar macrophages and circulating leucocytes (especially lymphocytes).
Phospholipidosis developed in rats receiving citalopram at daily doses of 120 mg/kg and slight vacuolization of peripheral lymphocytes was observed in mice at daily doses of 100 mg/kg, in the 52-week and 26-week studies, respectively. Both conditions were reversible within 3-4 weeks.
Retinal Degeneration/Atrophy in Rats: In the rat carcinogenicity study, a slight, dose-related increase in lens opacity was seen, affecting males only. In addition, increased incidence/severity of retinal degeneration/atrophy was seen in the high-dose group (80 mg/kg/day). The incidence was higher in females, however, more female than male rats survived the study. It was concluded by an independent pathologist that the retinal changes were most likely related to drug-induced pupillary dilatation (mydriasis) which increased the risk of retinal damage in the already light-sensitive albino rat.
Testicular Atrophy in Rats: In the 52-week rat toxicity study, testicular atrophy was seen at the 60 and 120 mg/kg/day doses of citalopram.
Convulsions and Death in Dogs: Toxicity studies in dogs revealed that citalopram administration led to fatal ventricular arrhythmias. Consequently, studies were undertaken to elucidate the mechanism of this effect and to determine its relevance to humans.
The studies have shown that: i.v. infusion of citalopram, at a dose of 20 mg/kg, led to convulsions. The blood levels of citalopram were 1950 ng/mL at this dose. In the presence of diazepam, also infused intravenously, higher doses of citalopram could be infused, namely up to 70 mg/kg (6800 ng/mL).
Intravenous infusion of the didemethyl metabolite of citalopram caused QT prolongation in a dose range of 5 to 22 mg/kg. The blood levels of the metabolite were 300 ng/mL at the 5 mg/kg dose. The QT prolongation was dose-dependent.
When citalopram, 20 mg/kg, and didemethylcitalopram, 5 mg/kg, were infused concomitantly (in the presence of diazepam in order to prevent convulsions), 5 out of 9 dogs died due to ventricular fibrillation. At these doses, the plasma levels of citalopram and didemethylcitalopram were 1950 ng/mL and 300 ng/mL, respectively.
As shown in the following table, there is a substantial difference in the plasma levels of citalopram and its metabolite in dogs and in humans at the recommended therapeutic doses. (See Table 5.)

Click on icon to see table/diagram/image

Reproduction Toxicity: Citalopram did not affect the reproductive performance of rats at dosages up to 16 mg/kg/day (males) and 32 mg/kg/day (females).
In the teratology studies in rats, effects were observed in the conceptuses at dosages that were toxic to the dams. Minimal developmental toxicity was evident at 32 mg/kg/day: manifested as low incidences of resorptions, slightly reduced fetal and pup weights, and small reversible delays in ossification and postnatal development.
In rabbits, dosages of 4.8 mg/kg/day and above were toxic to the dams, and 16 mg/kg/day and above caused deaths. There were no effects on embryo-fetal development at the highest dose that could be assessed (16 mg/kg/day).
In a rat embryo/fetal development study, oral administration of citalopram (32, 56, or 112 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased embryo/fetal growth and survival and an increased incidence of fetal abnormalities (including cardiovascular and skeletal defects) at the high dose, which is approximately 18 times the MRHD of 60 mg/day on a body surface area (mg/m²) basis. This dose was also associated with maternal toxicity (clinical signs, decreased body weight gain). The developmental, no-effect dose of 56 mg/kg/day is approximately 9 times the MRHD on a mg/m² basis. In a second embryo/fetal developmental study in rats conducted at similar dose levels, no increase in fetal abnormalities were observed.
In a rabbit study, no adverse effects on embryo/fetal development were observed at doses of up to 16 mg/kg/day, or approximately 5 times the MRHD on a mg/m² basis. Thus, teratogenic effects were observed at a maternally toxic dose in one embryo-foetal developmental study in the rats, but were not confirmed in a second rat study or in the rabbit.
When female rats were treated with citalopram (4.8, 12.8, or 32 mg/kg/day) from late gestation through weaning, increased offspring mortality during the first 4 days after birth and persistent offspring growth retardation were observed at the highest dose, which is approximately 5 times the MRHD on an mg/m² basis. The no-effect dose of 12.8 mg/kg/day is approximately 2 times the MRHD on an mg/m² basis. Similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses ≥ 24 mg/kg/day, approximately 4 times the MRHD on an mg/m² basis. A no-effect dose was not determined in that study.
Fertility: Animal data have shown that citalopram induces a reduction of fertility index and pregnancy index, reduction in number in implantation and abnormal sperm at exposure well in excess of human exposure.
Mutagenic Potential: Citalopram did not have mutagenic activity in most of the in vitro tests (Ames Salmonella assay; chromosome aberration assay in cultured human lymphocytes; gene mutation assay in cultured mouse lymphoma L5178Y) and in vivo tests (micronucleus test; unscheduled DNA synthesis). However, citalopram was mutagenic in some in vitro studies (Ames Salmonella assay and Chinese hamster lung cell assay).
Carcinogenicity: Citalopram did not show any carcinogenic potential in mice at daily doses of 40-240 mg/kg (1.5 years) and in rats at 8-80 mg/kg (2 years). There was an increased incidence of small intestine carcinoma in rats treated with 8 and 24 mg/kg/day of citalopram but not in rats treated with an 80 mg/kg/day dose.

Adults: pms-CITALOPRAM (citalopram hydrobromide) is indicated for: the symptomatic relief of depressive illness.
The relapse rate was significantly lower in citalopram hydrobromide-treated patients than in placebo-treated patients in two placebo-controlled studies that were conducted over a 24-week period in patients who responded to 6 or 8 weeks of acute treatment with citalopram hydrobromide (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions). Nevertheless, the physician who elects to use citalopram hydrobromide for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
Geriatrics (≥ 65 years of age): Elderly patients should be administered lower doses and a lower maximum dose (see Recommended Dose and Dosage Adjustment: Geriatrics (≥ 65 years of age) under Dosage & Administration and Use in Elderly under Precautions).
Pediatrics (< 18 years of age): pms-CITALOPRAM is not indicated for use in patients below the age of 18 (see General: Potential Association with Behavioral and Emotional Changes, Including Self-Harm under Precautions).

Dosing Considerations: pms-CITALOPRAM is not indicated for use in children under 18 years of age (see General: Potential Association with Behavioral and Emotional Changes, Including Self-Harm under Precautions).
General: pms-CITALOPRAM should be administered once daily, in the morning or evening, with or without food.
Recommended Dose and Dosage Adjustment: Adults: pms-CITALOPRAM should be administered as a single oral dose of 20 mg/day. In patients who do not respond adequately, an increase of dosage to a maximum of 40 mg/day should be considered. Dose increases should usually occur at intervals of no less than one week.
Treatment of Pregnant Women: The safety of citalopram hydrobromide during pregnancy has not been established. Therefore, pms-CITALOPRAM should not be used during pregnancy, unless, in the opinion of the physician, the expected benefits to the patient markedly outweigh the possible risk to the fetus.
Post-marketing reports indicate that some neonates exposed to SSRIs such as citalopram hydrobromide and other newer antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see Pregnant Women: Complications following late third trimester exposure to SSRIs under Use in Pregnancy & Lactation). When treating pregnant women with pms-CITALOPRAM during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering pms-CITALOPRAM in the third trimester.
Geriatrics (≥ 65 years of age): A longer half-life and decreased clearance have been demonstrated in the elderly, therefore lower doses and a lower maximum dose should be considered. It may be desirable to start at 10 mg daily and titrate upwards as needed and tolerated. A single oral dose of 20 mg/day is the recommended dose for most elderly patients. Some patients may respond to a 10 mg/day dose (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions). The dose may be titrated to a maximum of 20 mg/day if needed and tolerated. As with other SSRIs, caution should be exercised in treating elderly female patients who may be more susceptible to adverse events such as hyponatremia and SIADH (syndrome of inappropriate antidiuretic hormone secretion) (see Renal: Hyponatremia under Precautions).
Hepatic Impairment: Dosages should be restricted to the lower end of the dose range in patients with mild to moderate hepatic insufficiency. Accordingly, an initial single oral dose of 10 mg daily is recommended. Subsequently, the dose may be increased based on the patient's response and clinical judgement. Patients with reduced hepatic function should receive dosages of no more than 20 mg/day (see Hepatic/Biliary/Pancreatic: Hepatic Impairment under Precautions). Citalopram should be used with additional caution in patients with severe hepatic impairment.
Renal Impairment: No dosage adjustment is necessary for patients with mild to moderate renal impairment. Since there is no information available on the pharmacokinetic or pharmacodynamic effects of citalopram hydrobromide in patients with severe renal impairment, citalopram hydrobromide should be used with caution in these patients.
CYP2C19 Poor Metabolisers: An initial dose of 10 mg daily during the first two weeks of treatment is recommended for patients who are known to be poor metabolisers of CYP2C19. The dose may be increased to a maximum of 20 mg daily depending on individual patient response (see Pharmacology: Pharmacokinetics: Metabolism under Actions).
Maintenance Treatment: Evaluation of citalopram hydrobromide in two placebo-controlled studies has shown that its antidepressant efficacy was maintained for periods of up to 24 weeks, following 6 or 8 weeks of initial treatment (total of 32 weeks) (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions). In the flexible dose study, the great majority of patients were receiving 20 or 40 mg/day doses both at 12 and 24 weeks. During maintenance therapy, the dosage should be kept at the lowest effective level and patients should be periodically reassessed to determine the need for continued treatment.
Switching Patients To or From a MAOI: At least 14 days should elapse between discontinuation of a MAOI and initiation of therapy with citalopram hydrobromide. Similarly, at least 14 days should be allowed after stopping citalopram hydrobromide before starting a MAOI (see Monoamine Oxidase Inhibitors under Contraindications).
Discontinuation of pms-CITALOPRAM Treatment: Symptoms associated with the discontinuation or dosage reduction of citalopram hydrobromide have been reported. Patients should be monitored for these and other symptoms when discontinuing treatment or during dosage reduction (see General: Discontinuation Symptoms under Precautions and Clinical Trial Adverse Drug Reactions: Adverse Reactions following Discontinuation of Treatment (or Dose Reduction) under Adverse Reactions).
A gradual reduction in the dose over a period of at least one to two weeks rather than abrupt cessation is recommended to reduce the risk of withdrawal reactions. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, dose titration should be managed on the basis of the patient's clinical response (see General: Discontinuation Symptoms under Precautions and Clinical Trial Adverse Drug Reactions: Adverse Reactions following Discontinuation of Treatment (or Dose Reduction) under Adverse Reactions).
Missed dose: In the event that a dose is missed, the patient should take the next dose when it is due.

In clinical trials with racemic citalopram, there were no reports of fatal citalopram overdoses of up to 2000 mg. All patients recovered. Events of torsade de pointes have been reported during overdose with citalopram hydrobromide during post-market use (see Dosage & Administration; QT Prolongation under Contraindications; Cardiovascular: QT Prolongation and Torsades de Pointes under Precautions; Post-Market Adverse Drug Reactions under Adverse Reactions; Interactions). When specified, these overdoses were in the range of 800-1000 mg.
Comprehensive clinical data on citalopram overdose are limited and many cases involve concomitant overdoses of other drugs and/or alcohol. Fatal cases of citalopram overdose have been reported with citalopram alone; however, the majority of fatal cases have involved overdose with concomitant medications. Post-marketing reports of drug overdoses involving citalopram have included fatalities with citalopram alone as well as non-fatal overdoses of up to 5200 mg.
Although most patients recovered without sequelae, 3 fatalities with known overdoses of racemic citalopram alone have been reported in the literature (doses of 2800 mg, 2880 mg, and 3920 mg).
Fatal cases of serotonin syndrome have been reported in patients who took overdoses of moclobemide and citalopram hydrobromide (see Neurologic: Serotonin Syndrome/Neuroleptic Malignant Syndrome (NMS)-Like Events under Precautions). The plasma concentrations of moclobemide were between 16 and 90 mg/L (therapeutic range: 1 to 3 mg/L) and those of citalopram hydrobromide between 0.3 and 1.7 mg (therapeutic concentration: 0.3 mg/L). This indicates that a relatively low dose of citalopram hydrobromide, given with an overdose of moclobemide represents a serious risk for the patient.
Symptoms of Overdose: The following symptoms have been seen in reported overdose of citalopram: agitation, atrial and ventricular arrhythmia, bradycardia, bundle branch block, cardiac arrest, confusion, convulsion, coma, cyanosis, dizziness, ECG changes, hyperventilation, hypotension, hypertension, loss of consciousness, mydriasis, nausea, QRS prolongation, QT prolongation, rhabdomyolysis, seizure, serotonin syndrome, somnolence, stupor, sweating, tachycardia, torsade de pointes, tremor, and vomiting.
Management of Overdose: Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric lavage and use of activated charcoal should be considered. Gastric lavage should be carried out as soon as possible after oral ingestion. Cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive measures. There are no specific antidotes for citalopram hydrobromide.
ECG monitoring is advisable in case of overdose.
Due to the large volume of distribution of citalopram hydrobromide, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit.
In managing overdosage, the possibility of multiple drug involvement must be considered.

Patients who are hypersensitive to citalopram hydrobromide or to any ingredient in the formulation or component of the container. For a complete listing, see Description.
Monoamine Oxidase Inhibitors: Cases of serious reactions have been reported in patients receiving selective serotonin reuptake inhibitors (SSRIs) in combination with a monoamine oxidase inhibitor (MAOI) or the reversible MAOI (RIMA), moclobemide, and in patients who have recently discontinued an SSRI and have been started on a MAOI (see Interactions). With the co-administration of an SSRI with MAOI, there have been reports of serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible fluctuations of vital signs, and mental status changes, including extreme agitation progressing to delirium and coma. Some cases presented with features resembling serotonin syndrome.
Therefore, citalopram should not be used in combination with a MAOI or within 14 days of discontinuing treatment with a MAOI, (including linezolid, an antibiotic which is a reversible non-selective MAO inhibitor and methylene blue, which is a MAOI). Similarly, at least 14 days should elapse after discontinuing citalopram treatment before starting a MAOI.
Pimozide: Citalopram should not be used in combination with the antipsychotic drug pimozide, as results from a controlled study indicate that concomitant use is associated with an increased risk of QTc prolongation compared to pimozide alone. This apparent pharmacodynamic interaction occurred in the absence of a clinically significant pharmacokinetic interaction; the mechanism is unknown (see Interactions).
QT Prolongation: pms-CITALOPRAM (citalopram hydrobromide) is contraindicated in patients with known QT interval prolongation or with congenital long QT syndrome. (See Dosage & Administration; Overdosage; Cardiovascular: QT Prolongation and Torsades de Pointes under Precautions; Post-Market Adverse Drug Reactions under Adverse Reactions; Interactions.)

General: Potential Association with Behavioral and Emotional Changes, Including Self-Harm: Pediatrics: Placebo-Controlled Clinical Trial Data: Recent analyses of placebo-controlled clinical trial safety databases from SSRIs and other newer anti-depressants suggest that use of these drugs in patients under the age of 18 may be associated with behavioral and emotional changes, including an increased risk of suicidal ideation and behavior over that of placebo.
The small denominators in the clinical trial database, as well as the variability in placebo rates preclude reliable conclusions on the relative safety profiles among these drugs.
Adults and Pediatrics: Additional data: There are clinical trial and post-marketing reports with SSRIs and other newer anti-depressants, in both pediatrics and adults, of severe agitation-type adverse events coupled with self-harm and harm to others. The agitation-type events include: akathisia, agitation, disinhibition, emotional lability, hostility, aggression and depersonalization. In some cases, the events occurred within several weeks of starting treatment.
Rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behavior is advised in patients of all ages. This includes monitoring for agitation-type emotional and behavioral changes.
An FDA meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients aged 18 to 24 years with psychiatric disorders showed an increased risk of suicidal behaviours with antidepressants compared to placebo.
Discontinuation Symptoms: Patients currently taking citalopram should NOT be discontinued abruptly, due to risk of discontinuation symptoms. At the time that a medical decision is made to discontinue an SSRI or other newer antidepressant drug, a gradual reduction in the dose rather than an abrupt cessation is recommended.
Discontinuation of Treatment with Citalopram: Symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see Clinical Trial Adverse Drug Reactions: Adverse Reactions following Discontinuation of Treatment (or Dose Reduction) under Adverse Reactions).
When discontinuing treatment, patients should be monitored for symptoms which may be associated with discontinuation. The risk of discontinuation symptoms may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions.
Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.
Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more).
It is therefore advised that citalopram should be gradually tapered over a period of several weeks or months when discontinuing treatment, according to the patient's needs (see Recommended Dose and Dosage Adjustment: Discontinuation of pms-CITALOPRAM Treatment under Dosage & Administration).
If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, dose titration should be managed on the basis of the patient's clinical response (see Recommended Dose and Dosage Adjustment: Discontinuation of pms-CITALOPRAM Treatment under Dosage & Administration and Clinical Trial Adverse Drug Reactions: Adverse Reactions following Discontinuation of Treatment (or Dose Reduction) under Adverse Reactions).
Citalopram Treatment during Pregnancy - Effects on Newborns: In animal reproduction studies, citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses (see Pharmacology: Toxicology: Reproduction Toxicity under Actions). There are no adequate and well-controlled studies in pregnant women; therefore, citalopram should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus.
Post-marketing reports indicate that some neonates exposed to SSRIs and other antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. When treating a pregnant woman with citalopram during the third trimester, the physician should carefully consider the potential risks and benefits of treatment (see Recommended Dose and Dosage Adjustment: Treatment of Pregnant Women under Dosage & Administration; Pregnant Women: Complications following late third trimester exposure to SSRIs under Use in Pregnancy & Lactation; Nursing Women under Use in Pregnancy & Lactation).
Interference with Cognitive and Motor Performance: In studies in normal volunteers, citalopram hydrobromide in doses of 40 mg/day did not impair cognitive function or psychomotor performance. However, psychotropic medications may impair judgement, thinking or motor skills. Consequently, patients should be cautioned against driving a car or operating hazardous machinery until they are reasonably certain that pms-CITALOPRAM does not affect them adversely.
Bone Fracture Risk: Epidemiological studies show an increased risk of bone fractures following exposure to some antidepressants, including SSRIs/SNRIs. The risks appear to be greater at the initial stages of treatment, but significant increased risks were also observed at later stages of treatment. The possibility of fracture should be considered in the care of patients treated with pms-CITALOPRAM. Elderly patients and patients with important risk factors for bone fractures should be advised of possible adverse events which increase the risk of falls, such as dizziness and orthostatic hypotension, especially at the early stages of treatment but also soon after withdrawal. Preliminary data from observational studies show association of SSRIs/SNRIs and low bone mineral density in older men and women. Until further information becomes available, a possible effect on bone mineral density with long term treatment with SSRIs/SNRIs, including citalopram hydrobromide, cannot be excluded, and may be a potential concern for patients with osteoporosis or major risk factors for bone fractures.
Carcinogenesis and Mutagenesis: For animal data, see Pharmacology: Toxicology: Mutagenic Potential and Carcinogenicity under Actions.
Cardiovascular: Patients with Cardiac Disease: Citalopram has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical trials during the drug's premarketing assessment.
In clinical trials, citalopram hydrobromide caused small but statistically significant decreases in heart rate (see Clinical Trial Adverse Drug Reactions: ECG under Adverse Reactions). Consequently, caution should be observed when citalopram is initiated in patients with pre-existing slow heart rate.
QT Prolongation and Torsades de Pointes: Citalopram hydrobromide can cause a dose-dependent increase in the QT interval (see Dosage & Administration; Overdosage; QT Prolongation under Contraindications; Post-Market Adverse Drug Reactions under Adverse Reactions; Interactions).
Events of torsade de pointes, ventricular fibrillation, cardiac arrest, and sudden death have been reported during post-marketing use of citalopram hydrobromide. Torsade de pointes is a polymorphic ventricular tachyarrhythmia. Generally, the risk of torsade de pointes increases with the magnitude of QT/QTc prolongation produced by the drug. Torsade de pointes may be asymptomatic or experienced by the patient as dizziness, palpitations, syncope, or seizures. If sustained, torsade de pointes can progress to ventricular fibrillation and sudden cardiac death.
A randomized, double-blind, placebo- and positive-controlled, crossover study was performed in healthy subjects (N=119) to examine the effects of citalopram 20 mg/day and 60 mg/day on ECG intervals (individually corrected QTcNi interval) when administered according to an escalating multiple dose regimen (9 days at 20 mg/day, 4 days at 40 mg/day, 9 days at 60 mg/day). The maximum mean (upper bound of the 95% one-sided confidence interval) differences from placebo were 8.5 (10.8) and 18.5 (21.0) msec for 20 mg and 60 mg citalopram, respectively. The effects of the 40 mg/day dose were not studied, but are predicted to be approximately 13 ms (estimate value on QTcNI).
Citalopram hydrobromide should not be dosed above 40 mg/day.
In patients who are CYP2C19 poor metabolizers or patients taking concomitant cimetidine or another CYP2C19 inhibitor, citalopram hydrobromide should not be dosed over 20 mg/day.
Hypokalemia and hypomagnesemia should be corrected prior to initiation of treatment and periodically monitored.
ECG monitoring is recommended in patients with risk factors for torsades de pointes, such as congestive heart failure, recent myocardial infarction, bradyarrhythmias, or patients on concomitant medications that prolong the QT interval or in patients with altered metabolism. e.g. liver impairment.
Endocrine and Metabolism: Diabetic Patients: Citalopram hydrobromide has not been systematically evaluated in diabetic patients since diabetes constituted an exclusion criterion. Although 13 patients did receive insulin during the studies, this number is too small to determine whether citalopram hydrobromide affects the response to insulin. Rare events of hypoglycemia were reported. Treatment with an SSRI in patients with diabetes may alter glycaemic control (hypoglycaemia and hyperglycaemia). pms-CITALOPRAM should be used with caution in diabetic patients on insulin or other antidiabetic drugs.
Hematologic: Abnormal Bleeding: SSRIs and SNRIs, including citalopram hydrobromide, may increase the risk of bleeding events by causing abnormal platelet aggregation. Concomitant use of acetylsalicylic acid (ASA), nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin and other anticoagulants may add to the risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening haemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of pms-CITALOPRAM and NSAIDs, ASA, or other drugs that affect coagulation (see Interactions).
Caution is advised in patients with a history of bleeding disorder or predisposing conditions (e.g. thrombocytopenia).
Hepatic/Biliary/Pancreatic: Hepatic Impairment: In subjects with hepatic impairment, citalopram hydrobromide clearance was significantly decreased and plasma concentrations, as well as elimination half-life significantly increased (see Pharmacology: Pharmacokinetics: Special Populations and Conditions: Hepatic Insufficiency under Actions). Consequently, the use of pms-CITALOPRAM in hepatically impaired patients should be approached with caution and a lower maximum dosage is recommended (see Recommended Dose and Dosage Adjustment: Hepatic Impairment under Dosage & Administration).
Neurologic: Seizures: Citalopram hydrobromide has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the premarketing testing of citalopram hydrobromide. In clinical trials, seizures occurred in 0.25% of patients treated with citalopram hydrobromide and in 0.23% patients treated with placebo. Like other antidepressants, pms-CITALOPRAM should be used with caution in patients with a history of seizure disorder. The drug should be discontinued in any patient who develops seizures.
Serotonin Syndrome/Neuroleptic Malignant Syndrome (NMS)-Like Events: On rare occasions serotonin syndrome or neuroleptic malignant syndrome-like events have occurred in association with treatment with SSRIs, including citalopram, particularly when given in combination with other serotonergic and/or neuroleptic drugs. As these syndromes may result in potentially life-threatening conditions, treatment with pms-CITALOPRAM should be discontinued if such events (characterized by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated. pms-CITALOPRAM should not be used in combination with MAO inhibitors or serotonin-precursors (such as L-tryptophan, oxitriptan) and should be used with caution in combination with other serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort) due to the risk of serotonergic syndrome (see Monoamine Oxidase Inhibitors under Contraindications and Overview: Serotonergic Drugs and Triptans (5HT₁ agonists) under Interactions).
Ophthalmologic: Angle-Closure Glaucoma: As with other antidepressants, pms-CITALOPRAM can cause mydriasis, which may trigger an angle-closure attack in a patient with anatomically narrow ocular angles. Healthcare providers should inform patients to seek immediate medical assistance if they experience eye pain, changes in vision or swelling or redness in or around the eye.
Psychiatric: Suicide: Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Therefore, high risk patients should be closely supervised throughout therapy with citalopram hydrobromide and consideration should be given to the possible need for hospitalization. In order to minimize the opportunity for overdosage, prescription for citalopram hydrobromide should be written for the smallest quantity of drug consistent with good patient management.
Other psychiatric conditions for which citalopram is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are at greater risk of suicidal thoughts or suicide attempts and should receive careful monitoring during treatment. In addition, there is a possibility of an increased risk of suicidal behaviour in young adults.
Patients (and caregivers of patients) should be alerted about the need to monitor for the emergence of such events and to seek medical advice immediately if these symptoms present. (See General: Potential Association with Behavioral and Emotional Changes, Including Self-Harm as previously mentioned.)
Activation of Mania/Hypomania: In placebo-controlled trials with citalopram hydrobromide, some of which included patients with bipolar disorder, mania/hypomania was reported in 0.1% of 1027 patients treated with citalopram hydrobromide versus none of the 426 patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with other marketed antidepressants. If a patient enters a manic phase, pms-CITALOPRAM should be discontinued.
As with all drugs effective in the treatment of depression, pms-CITALOPRAM should be used with caution in patients with a history of mania. A major depressive episode may be the initial presentation of bipolar disorder. Patients with bipolar disorder may be at an increased risk of experiencing manic episodes when treated with antidepressants alone. Therefore, the decision to initiate symptomatic treatment of depression should only be made after patients have been adequately assessed to determine if they are at risk for bipolar disorder.
Electroconvulsive Therapy (ECT): The safety and efficacy of the concurrent use of citalopram hydrobromide and ECT have not been studied and therefore, caution is advisable.
Renal: Hyponatremia: Hyponatremia and SIADH (syndrome of inappropriate antidiuretic hormone secretion) have been reported as a rare adverse event with use of citalopram hydrobromide, as with other SSRIs. The majority of these occurrences have been in elderly individuals, some in patients taking diuretics or who were otherwise volume-depleted. Elderly female patients in particular seem to be a group at risk.
Renal Impairment: No dosage adjustment is needed in patients with mild to moderate renal impairment. Since, no information is available on the pharmacokinetic or pharmacodynamic effects of citalopram hydrobromide in patients with severely reduced renal function (creatinine clearance < 30 mL/min), pms-CITALOPRAM should be used with caution in these patients.
Male Fertility: Animal data have shown that citalopram may affect sperm quality (see Pharmacology: Toxicology: Fertility under Actions). Human case reports with some SSRIs have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed.
Use in Children: pms-CITALOPRAM is not indicated for use in patients below the age of 18 years (see General: Potential Association with Behavioral and Emotional Changes, Including Self-Harm as previously mentioned).
Use in Elderly: Elderly patients should be administered lower doses and a lower maximum dose (see Recommended Dose and Dosage Adjustment: Geriatrics (≥ 65 years of age) under Dosage & Administration). In premarketing clinical trials, 800 elderly patients (≥65 years of age) have been treated with citalopram hydrobromide. Of these patients 298 were ≥75 years old. In a pharmacokinetic study (N=11, age 73 to 90 years), clearance was substantially decreased and half-life prolonged. In a multiple-dose pharmacokinetic study, the area under the curve (AUC) and half-life of S-citalopram were increased by approximately 50% at steady-state in elderly subjects as compared to young subjects. (See Pharmacology: Pharmacokinetics: Special Populations and Conditions: Geriatrics under Actions.) In a 6-week placebo-controlled study, approximately equal numbers of patients received citalopram hydrobromide at 20 or 30 mg per day, as the final dose. In about 5% of patients, the final dose was 10 mg per day (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).

Pregnant Women: The safety of citalopram hydrobromide during pregnancy has not been established. Therefore, pms-CITALOPRAM should not be used during pregnancy, unless, in the opinion of the physician, the expected benefits to the patient markedly outweigh the possible risk to the fetus.
Complications following late third trimester exposure to SSRIs: Post-marketing reports indicate that some neonates exposed to SSRIs such as citalopram hydrobromide and other antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and other newer anti-depressants, or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see Neurologic: Serotonin Syndrome/Neuroleptic Malignant Syndrome (NMS)-Like Events under Precautions). When treating a pregnant woman with citalopram hydrobromide during the third trimester, the physician should carefully consider the potential risks and benefits of treatment (see Recommended Dose and Dosage Adjustment: Treatment of Pregnant Women under Dosage & Administration).
Risk of PPHN and exposure to SSRIs (including citalopram hydrobromide): Epidemiological studies on persistent pulmonary hypertension of the newborn (PPHN) have shown that the use of SSRIs (including citalopram) in pregnancy, particularly use in late pregnancy, was associated with an increased risk of PPHN. PPHN occurs in 1-2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy (Odds Ratio 6.1, 95% CI 2.2-16.8). A study using data from the Swedish Medical Birth Register for 831,324 infants born in 1997-2005 found an increased risk of PPHN of approximately 2-fold associated with patient-reported maternal use of SSRIs in the first trimester of pregnancy (Risk Ratio 2.4, 95% CI 1.2-4.3), and an increased risk of PPHN of approximately 4-fold associated with a combination of patient-reported maternal use of SSRIs in the first trimester and an antenatal SSRI prescription in later pregnancy (Risk Ratio 3.6, 95% CI 1.2-8.3).
Nursing Women: The safety of citalopram hydrobromide during lactation has not been established. citalopram hydrobromide is excreted in human milk. pms-CITALOPRAM should not be administered to nursing mothers unless, in the opinion of the treating physician, the expected benefits to the patient markedly outweigh the possible risks to the child; in which case the infant should be closely monitored.

Adverse Drug Reaction Overview: During the premarketing clinical development, 3652 patients received citalopram hydrobromide for the treatment of depression. Of these patients, 66% were females and 34% were males. The mean age of the patients was 50 years, with 70% being <60 years old (30% <40 years old, 40% 40 to 59 years old) and 30% being ≥60 years old. Adverse events observed with citalopram hydrobromide are in general mild and transient. They usually attenuate during the first one or two weeks of treatment.
Clinical Trial Adverse Drug Reactions: Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
Adverse Findings Observed in Short-term, Placebo-controlled Trials: Adverse Reactions Leading to Discontinuation of Treatment: From the short-term (4 to 6 weeks) placebo-controlled, Phase III clinical trials, 15.9% (163/1027) of the citalopram hydrobromide treated patients discontinued treatment due to an adverse event. The discontinuation rate in the placebo-treated patients was 7.7% (33/426).
The events associated with discontinuation of citalopram hydrobromide in 1% or more of patients at a rate of at least twice that of placebo, were as follows: nausea (4.1% vs. 0.0%), insomnia (2.4% vs. 1.2%), somnolence (2.4% vs. 1.2%), dizziness (2.3% vs. 0.7%), vomiting (1.3% vs. 0.0%), agitation (1.2% vs. 0.0%), asthenia (1.1% vs. 0.5%), and dry mouth (1.1% vs. 0.2%).
Incidence of Adverse Events in Placebo-controlled Studies: Table 6 enumerates the incidence of treatment emergent adverse events that occurred in 1027 depressed patients who received citalopram hydrobromide at doses ranging from 10 to 80 mg/day in placebo-controlled trials of up to 6 weeks in duration. Events included are those occurring in 2% or more of patients treated with citalopram hydrobromide, and for which the incidence in patients treated with citalopram hydrobromide was greater than the incidence in placebo-treated patients. Reported adverse events were classified using the standard World Health Organization (WHO)-based dictionary terminology.
The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied. (See Table 6.)

Click on icon to see table/diagram/image

The following events had a higher incidence in the placebo group compared to the citalopram group: asthenia, back pain, headache, dizziness, constipation, palpitation, insomnia, abnormal vision.
Most Frequent Adverse Events: Adverse events that occurred in citalopram hydrobromide treated patients in the course of the short-term, placebo-controlled trials with an incidence greater than, or equal to, 10% were: nausea, dry mouth, somnolence, and increased sweating (Table 6).
Dose Dependency of Adverse Events: The potential relationship between the dose of citalopram hydrobromide and the incidence of an adverse event was examined in a fixed dose short-term, placebo-controlled study in which patients received citalopram hydrobromide at doses of 10, 20, 40 or 60 mg per day. The incidence of diarrhea, dry mouth, fatigue, insomnia, increased sweating, nausea and somnolence was dose-related.
Male and Female Sexual Dysfunction with SSRIs: While sexual dysfunction is often part of depression and other psychiatric disorders, there is increasing evidence that treatment with SSRIs may induce sexual side effects. This is a difficult area to study because patients may not spontaneously report symptoms of this nature, and therefore, it is thought that sexual side effects with SSRIs may be underestimated.
In placebo-controlled, short-term clinical trials, the reported incidence of decreased libido, ejaculation disorders (primarily ejaculation delay and ejaculation failure), and impotence in male depressed patients receiving citalopram hydrobromide (N=404) was 3.7%, 6.2%, and 3.2%, respectively. In female depressed patients receiving citalopram hydrobromide (N=623), the reported incidence of decreased libido and anorgasmia was 1.3% and 1.1%, respectively. The reported incidence of each of these adverse events was ≤1% among male and female depressed patients receiving placebo.
Weight Changes: Patients treated with citalopram hydrobromide in controlled trials experienced a weight loss of about 0.5 kg compared to no change for placebo patients.
ECG: Retrospective analyses of electrocardiograms in citalopram hydrobromide treated (N=779 <60 years and N=313 ≥60 years) and placebo-treated (N=74 <60 years and N=43 ≥60 years) patients indicated that citalopram hydrobromide decreases heart rate. In patients <60 years old, the mean decrease was approximately 5 bpm, while in patients ≥60 years old, mean decreases ranged between 5 to 10 bpm. Following the initial drop, heart rate remained decreased but stable over prolonged periods of time (up to one year in over 100 younger and over 50 elderly patients). The effect was reversible within approximately a week after stopping treatment.
In the 6-week, fixed dose, dose-response study, the mean decreases in heart rate ranged between 2-6 bpm in the 20-60 mg/day dose range, but the effect did not seem to be dose-related and was independent of gender. In placebo-treated patients heart rates remained unaffected. The differences in heart rates between citalopram hydrobromide and placebo-treated patients were statistically significant. ECG parameters, including QT interval, remained unaffected.
Adverse Reactions following Discontinuation of Treatment (or Dose Reduction): There have been reports of adverse reactions upon the discontinuation of citalopram hydrobromide (particularly when abrupt), including but not limited to the following: dizziness, abnormal dreams, sensory disturbances (including paresthesias and electric shock sensations), agitation or anxiety, emotional indifference, impaired concentration, headache, migraine, tremor, nausea and/or vomiting, sleep disturbances (including insomnia and intense dreams), confusion, diarrhoea, palpitations, irritability, visual disturbances and sweating or other symptoms which may be of clinical significance (see Recommended Dose and Dosage Adjustment: Discontinuation of pms-CITALOPRAM Treatment under Dosage & Administration and General: Discontinuation Symptoms under Precautions).
Patients should be monitored for these or any other symptoms. A gradual reduction in the dosage over a period of at least one to two weeks, rather than abrupt cessation is recommended to reduce the risk of withdrawal reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when citalopram treatment is no longer required, gradual discontinuation by dose tapering should be carried out. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, dose titration should be managed on the basis of the patient's clinical response. Symptoms associated with discontinuation have been reported for other selective serotonin reuptake inhibitors (see Recommended Dose and Dosage Adjustment: Discontinuation of pms-CITALOPRAM Treatment under Dosage & Administration and General: Discontinuation Symptoms under Precautions).
Additional Adverse Events Observed During the Premarketing Evaluation of Citalopram Hydrobromide: The events listed as follows include all adverse events that were reported in the overall development program of citalopram hydrobromide (N=3652). All reported events are included except those already listed in Table 6 and those events which occurred in only one patient. It is important to emphasize that, although the events reported occurred during treatment with citalopram hydrobromide, they were not necessarily caused by it. The events are enumerated using the following criteria: Frequent: adverse events that occurred on one or more occasions in at least 1/100 patients.
Infrequent: adverse events that occurred in less than 1/100 patients but at least in 1/1000 patients.
Rare: adverse events that occurred in fewer than 1/1000 patients.
Body as a Whole - General Disorders: Frequent: influenza-like symptoms, non-pathological trauma, pain.
Infrequent: alcohol intolerance, allergic reaction, allergy, chest pain, edema, hot flushes, leg pain, malaise, rigors, syncope.
Rare: peripheral edema, sudden death, traumatic injury.
Cardiovascular Disorders: Frequent: postural hypotension, tachycardia.
Infrequent: angina pectoris, arrhythmia, bradycardia, cardiac failure, cerebrovascular disorders, edema dependent, extrasystoles, flushing, hypertension, hypotension, myocardial infarction, myocardial ischemia, peripheral ischemia.
Rare: aggravated hypertension, bundle branch block, cardiac arrest, coronary artery disorder, ECG abnormal, heart disorder, phlebitis, supraventricular extrasystoles.
Central and Peripheral Nervous System Disorders: Frequent: migraine, paraesthesia.
Infrequent: abnormal gait, ataxia, convulsions, dysphonia, dystonia, extrapyramidal disorder, hyperkinesia, hypertonia, hypoesthesia, hypokinesia, involuntary muscle contractions, leg cramps, neuralgia, speech disorder, vertigo.
Rare: abnormal coordination, convulsions grand mal, hyperesthesia, ptosis, sensory disturbance, stupor.
Collagen Disorders: Rare: rheumatoid arthritis.
Endocrine Disorders: Rare: goiter, gynecomastia, hypothyroidism.
Gastrointestinal System Disorders: Frequent: flatulence.
Infrequent: colitis, dental abscess, dysphagia, eructation, gastritis, gastroenteritis, gastrointestinal disorder (not specified), hemorrhoids, increased saliva, teeth-grinding, toothache.
Rare: appendicitis, esophagitis, gastric ulcer, gastroesophageal reflux, gingivitis, stomatitis, tooth disorder, ulcerative stomatitis.
Hematopoietic and Lymphatic Disorders: Infrequent: anemia, epistaxis, leukocytosis, purpura.
Rare: coagulation disorder, gingival bleeding, granulocytopenia, hematoma, leukopenia, lymphadenopathy, lymphocytosis, pulmonary embolism.
Liver and Biliary System Disorders: Infrequent: cholecystitis, cholelithiasis, increased gamma-GT, increased ALT.
Rare: bilirubinemia, increased AST, jaundice.
Metabolic and Nutritional Disorders: Frequent: appetite decreased, weight decrease, weight increase.
Infrequent: leg edema, xerophthalmia.
Rare: dehydration, edema, hypoglycemia, hypokalemia, increased alkaline phosphatase, obesity, thirst.
Musculo-Skeletal System Disorders: Infrequent: arthralgia, arthritis, arthrosis, dystonia, muscle weakness, myalgia.
Rare: bone disorder, bursitis, osteoporosis, tendon disorder.
Neoplasm: Rare: breast neoplasm malignant female.
Psychiatric Disorders: Frequent: abnormal dreaming, aggravated depression, amnesia, apathy, confusion, depression, impaired concentration, increased appetite, sleep disorder, suicide attempt.
Infrequent: abnormal thinking, aggressive reaction, delusion, depersonalization, drug abuse, drug dependence, emotional lability, euphoria, hallucination, increased libido, manic reaction, neurosis, paranoid reaction, paroniria, psychosis, psychotic depression.
Rare: catatonic reaction, hysteria, personality disorder.
Reproductive Disorders, Female: Frequent: Abnormal orgasm.
Infrequent: amenorrhea, breast pain, lactation nonpuerperal, menorrhagia, menstrual disorder, premenstrual syndrome, salpingitis, unintended pregnancy, vaginal dryness, vaginitis.
Rare: breast enlargement, vaginal hemorrhage.
Reproductive Disorders, Male: Infrequent: penis disorder, prostatic disorder, testis disorder.
Resistance Mechanism Disorders: Infrequent: abscess, fungal infection, herpes simplex infection, otitis media, viral infection.
Rare: bacterial infection, moniliasis, sepsis.
Respiratory System Disorders: Infrequent: bronchitis, coughing, dyspnea, pneumonia.
Rare: asthma, bronchospasm, increased sputum, laryngitis, pneumonitis, respiratory disorder.
Skin and Appendage Disorders: Frequent: pruritus, rash.
Infrequent: acne, alopecia, dermatitis, dry skin, eczema, photosensitivity reaction, psoriasis, rash erythematous, rash maculo-papular, skin discoloration, urticaria.
Rare: cellulitis, decreased sweating, hypertrichosis, melanosis, pruritus ani.
Special Senses, Vision, Hearing and Vestibular Disorders: Frequent: abnormal accommodation.
Infrequent: conjunctivitis, earache, eye pain, mydriasis, taste perversion, tinnitus.
Rare: eye abnormality, keratitis, photophobia.
Urinary System Disorders: Frequent: polyuria.
Infrequent: abnormal urine, cystitis, hematuria, micturition frequency, urinary incontinence, urinary retention, urinary tract infection.
Rare: dysuria, facial edema, oliguria, renal calculus, renal pain.
Post-Market Adverse Drug Reactions: During the 22 year of post marketing experience, it is estimated that more than 138 million patients have been treated with citalopram, which corresponds to more than 34 million patient-years of treatment.
The following adverse events have been identified during post-approval use of citalopram. These events are reported voluntarily from a population of uncertain size, and it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. (See Table 7.)

Click on icon to see table/diagram/image

Serious Drug Interactions: Monoamine Oxidase Inhibitors; Pimozide. See Contraindications.
Overview: Alcohol: Although citalopram hydrobromide did not potentiate the cognitive and psychomotor effects of alcohol in volunteers, the concomitant use of alcohol and citalopram hydrobromide should be avoided.
Cimetidine: Citalopram hydrobromide should not be dosed above 20 mg/day in patients receiving cimetidine.
CNS drugs: Drug interactions have not been specifically studied between citalopram and other centrally acting drugs. Given the primary CNS effects of citalopram, caution should be used as with other SSRIs when citalopram is taken in combination with other centrally acting drugs.
Cytochrome P450 Isozymes: Using in vitro models of human liver microsomes, the biotransformation of citalopram to its demethyl metabolites was shown to depend on both CYP2C19 and CYP3A4, with a small contribution from CYP2D6. Studies have also indicated that citalopram is a weak inhibitor of CYP2D6 and CYP2C19 and a weak or negligible inhibitor of CYP3A4, CYP1A2, CYP2C9 and CYP2E1. Although citalopram has a low potential for clinically significant drug interactions, caution is recommended, when citalopram is co-administered with drugs that are mainly metabolized by CYP2D6, and that have a narrow therapeutic index.
One in vitro study using human liver microsomes has shown that ketoconazole and omeprazole reduced the rate of formation of the demethylcitalopram metabolite of citalopram to 45-60% and 75-85% of control, respectively. As data are not available from multi-dose pharmacokinetic studies, the possibility that the clearance of citalopram will be decreased when citalopram hydrobromide is administered with a potent inhibitor of CYP3A4 (e.g., ketoconazole, itraconazole, fluconazole or erythromycin), or a potent inhibitor of CYP2C19 (e.g., omeprazole, esomeprazole, fluvoxamine, lansoprazole, ticlopidine), should be considered.
Citalopram 20 mg/day is the maximum recommended dose for patients taking concomitant CYP2C19 inhibitors because of the risk of QT prolongation.
In addition, a single-dose study of escitalopram co-administered with a multiple-dose regimen of cimetidine, a non-specific CYP inhibitor, led to significant changes in most of the pharmacokinetic parameters of escitalopram. The overall metabolic pathways for escitalopram and citalopram are qualitatively similar and the interaction potential for escitalopram is expected to closely resemble that of citalopram. Thus, this allows for extrapolation to previous studies with escitalopram.
Various scientific publications have acknowledged that the main components in grapefruit juice may act as a CYP3A4 inhibitor. Citalopram is also metabolized by other isoenzymes not affected by grapefruit juice, namely CYP2C19 and CYP2D6.
Drugs Affecting Platelet Function (e.g. NSAIDs, ASA and other anticoagulants): Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID, ASA or other anticoagulants may potentiate the risk of bleeding.
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are co-administered with warfarin. Patients receiving warfarin therapy should be carefully monitored when citalopram is initiated or discontinued. (See Hematologic: Abnormal Bleeding under Precautions.)
Drugs That Prolong the QT Interval: ECG monitoring is recommended if citalopram hydrobromide is administered with concomitant medications that have demonstrated prolongation of the QT interval. (See Dosage & Administration; QT Prolongation under Contraindications; Cardiovascular: QT Prolongation and Torsades de Pointes under Precautions; Post-Market Adverse Drug Reactions under Adverse Reactions; Cimetidine and Cytochrome P450 Isozymes as previously mentioned.)
Drugs known to prolong the QT/QTc: The concomitant use of citalopram with another drug known to prolong the QT/QTc interval should be carefully considered to determine that the therapeutic benefit outweighs the potential risk. Drugs that have been associated with QT/QTc interval prolongation and/or torsade de pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QT/QTc prolongation and/or torsade de pointes: class IA antiarrhythmics (e.g., procainamide, disopyramide); class III antiarrhythmics (e.g., amiodarone, sotalol, ibutilide); class IC antiarrhythmics (e.g., propafenone); antipsychotics (e.g., chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone); antidepressants (e.g., fluoxetine, venlafaxine, tricyclic/tetracyclic antidepressants e.g., amitriptyline, imipramine, maprotiline); opioids (e.g., methadone); macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin, telithromycin, tacrolimus); quinolone antibiotics (e.g., moxifloxacin, levofloxacin, ciprofloxacin); antimalarials (e.g., quinine, chloroquine); azole antifungals (e.g., ketoconazole, fluconazole, voriconazole); domperidone; 5-hydroxytryptamine (5-HT)3 receptor antagonists (e.g., ondansetron); tyrosine kinase inhibitors (e.g., sunitinib, nilotinib, lapatinib); histone deacetylase inhibitors (e.g., vorinostat); beta-2 adrenoceptor agonists (e.g., salmeterol, formoterol).
The use of citalopram should be carefully considered with drugs that can disrupt electrolyte levels (see Precautions), including, but not limited to, the following: loop, thiazide, and related diuretics; laxatives and enemas; amphotericin B; high dose corticosteroids.
Monoamine Oxidase Inhibitors: In patients receiving SSRIs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes, including extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on a MAOI. Some cases presented with features resembling serotonin syndrome or neuroleptic malignant syndrome. Citalopram hydrobromide should not be used in combination with a MAOI, (including linezolid, an antibiotic which is a reversible non-selective MAO inhibitor and methylene blue, which is a MAOIs) or within 14 days of discontinuing treatment with a MAOI. Similarly, at least 14 days should elapse after discontinuing citalopram hydrobromide treatment before starting a MAOI (see Monoamine Oxidase Inhibitors under Contraindications).
Serotonergic Drugs: Based on the mechanism of action of citalopram and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, serotonin reuptake inhibitors, lithium, St. John's Wort, fentanyl and its analogues, dextromethorphan, tramadol, tapentadol, meperidine, methadone and pentazocine. (See Neurologic: Serotonin Syndrome/Neuroleptic Malignant Syndrome (NMS)-Like Events under Precautions.) Concomitant use of citalopram hydrobromide and MAO inhibitors (including linezolid and methylene blue), is contraindicated (see Monoamine Oxidase Inhibitors under Contraindications).
Triptans (5HT₁ agonists): Cases of life-threatening serotonin syndrome have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans. If concomitant treatment with citalopram hydrobromide and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see Neurologic: Serotonin Syndrome/Neuroleptic Malignant Syndrome (NMS)-Like Events under Precautions).
Racemic Citalopram: pms-CITALOPRAM is a racemic mixture of R-citalopram and S-citalopram, the latter being the active isomer. As escitalopram, is the active isomer of racemic citalopram, the two drugs should not be taken together.
Other Drugs: No pharmacodynamic interactions have been noted in clinical trials where citalopram hydrobromide has been given concomitantly with benzodiazepines (anxiolytics/hypnotics), analgesics (NSAIDs, non-NSAIDs), antihistamines, antihypertensives or other cardiovascular drugs. Pharmacokinetic interactions between citalopram and these drugs were not specifically studied.
Drug-Drug Interactions: Where studies are described in this section, they were carried out in young, healthy, mostly male volunteers. In addition, some of the studies, namely interactions with metoprolol, warfarin, digoxin, imipramine, and levomepromazine, utilized only single doses of these drugs, although citalopram hydrobromide was given repeatedly to attain steady state. Thus, data are not available in patients who would be receiving these drugs on an ongoing basis at therapeutic doses. (See Tables 8a and 8b.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Drug-Food Interactions: Although there is a theoretical possibility of pharmacokinetic drug product interactions resulting from co-administration of citalopram with grapefruit juice, the onset of an interaction is considered unlikely (see Overview: Cytochrome P450 Isozymes as previously mentioned).
Drug-Herb Interactions: St. John's Wort: In common with other SSRIs, pharmacodynamic interactions between citalopram and the herbal remedy St. John's Wort may occur and may result in undesirable effects.
Drug-Laboratory Interactions: Interactions with laboratory tests have not been established.

pms-CITALOPRAM tablets should be stored in a dry place and store below 25°C.

Antidepressants

N06AB04 - citalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.

P₁S₁S₃